These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28462602)

  • 1. 'Big data' approaches for novel anti-cancer drug discovery.
    Benstead-Hume G; Wooller SK; Pearl FMG
    Expert Opin Drug Discov; 2017 Jun; 12(6):599-609. PubMed ID: 28462602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
    Murray HC; Dun MD; Verrills NM
    Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.
    Wajnberg G; Passetti F
    Expert Opin Drug Discov; 2016; 11(3):257-68. PubMed ID: 26787005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modeling in cancer drug discovery.
    Wang Z; Deisboeck TS
    Drug Discov Today; 2014 Feb; 19(2):145-50. PubMed ID: 23831857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery.
    Yarwood A; Eyre S; Worthington J
    Expert Opin Drug Discov; 2016 Aug; 11(8):805-13. PubMed ID: 27267163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of molecular hybrids in drug discovery.
    Bérubé G
    Expert Opin Drug Discov; 2016; 11(3):281-305. PubMed ID: 26727036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational modeling in melanoma for novel drug discovery.
    Pennisi M; Russo G; Di Salvatore V; Candido S; Libra M; Pappalardo F
    Expert Opin Drug Discov; 2016 Jun; 11(6):609-21. PubMed ID: 27046143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer drug discovery: recent innovative approaches to tumor modeling.
    Lovitt CJ; Shelper TB; Avery VM
    Expert Opin Drug Discov; 2016 Sep; 11(9):885-94. PubMed ID: 27454169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Embracing synthetic lethality of novel anticancer therapies.
    Kamal A; Shaik TB; Malik MS
    Expert Opin Drug Discov; 2015 Oct; 10(10):1119-32. PubMed ID: 26211783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new approach to assess drug sensitivity in cells for novel drug discovery.
    Mazzarella L; Curigliano G
    Expert Opin Drug Discov; 2018 Apr; 13(4):339-346. PubMed ID: 29415581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optogenetics in cancer drug discovery.
    Kiełbus M; Czapiński J; Odrzywolski A; Stasiak G; Szymańska K; Kałafut J; Kos M; Giannopoulos K; Stepulak A; Rivero-Müller A
    Expert Opin Drug Discov; 2018 May; 13(5):459-472. PubMed ID: 29447015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET inhibitors in cancer therapeutics: a patent review.
    Ghoshal A; Yugandhar D; Srivastava AK
    Expert Opin Ther Pat; 2016; 26(4):505-22. PubMed ID: 26924192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.
    Vari S; Pilotto S; Maugeri-Saccà M; Ciuffreda L; Cesta Incani U; Falcone I; Del Curatolo A; Ceribelli A; Gelibter A; De Maria R; Tortora G; Cognetti F; Bria E; Milella M
    Expert Opin Drug Discov; 2013 Nov; 8(11):1381-97. PubMed ID: 24088065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.
    Safavi M; Sabourian R; Abdollahi M
    Expert Opin Drug Discov; 2016 Oct; 11(10):939-56. PubMed ID: 27454411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Antineoplastic Targets with Systems Approaches, Using Resveratrol as an In-Depth Case Study.
    Singh N; Freiesleben S; Wolkenhauer O; Shukla Y; Gupta SK
    Curr Pharm Des; 2017; 23(32):4773-4793. PubMed ID: 28699531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery.
    Oliveira PA; Gil da Costa RM; Vasconcelos-Nóbrega C; Arantes-Rodrigues R; Pinto-Leite R
    Expert Opin Drug Discov; 2016 Jun; 11(6):599-607. PubMed ID: 27077499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current mathematical models for cancer drug discovery.
    Carrara L; Lavezzi SM; Borella E; De Nicolao G; Magni P; Poggesi I
    Expert Opin Drug Discov; 2017 Aug; 12(8):785-799. PubMed ID: 28595492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.